Clincosm LogoSign in Get a demo

Anterior Segment Anatomic Parameters for Risk Profiling of Primary Angle-closure Glaucoma

Sponsor
Min Ke (Other)
Overall Status
Completed
CT.gov ID
NCT06143943
Collaborator
(none)
168
Enrollment
1
Location
3.2
Actual Duration (Months)
52.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this observational study is to examine the anterior segment anatomical parameters associated with the scleral spur and cornea for risk profiling of primary angle-closure glaucoma (PACG). The main question it aims to answer is:

• Are there new anatomical parameters of the anterior segment of the eye that can be used early for risk profiling for PACG? Researchers will compare PACG and narrow angle groups to see if there are some anatomical parameters that can distinguish the two.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    We aimed to examine the anterior segment anatomical parameters associated with the scleral spur and cornea for risk profiling of primary angle-closure glaucoma (PACG).

    This retrospective study included 84 patients with PACG and 84 patients with narrow angles (NA). We collected parametric measurements obtained using anterior-segment optical coherence tomography and IOLMaster 700. Univariate and multivariate logistic regression models were used to compare the ocular parameters between the NA and PACG groups as well as to identify risk factors for PACG. The predictive performance of each parameter was evaluated using the area under the receiver operating characteristic curve (AUROC) analysis.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    168 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Retrospective
    Official Title:
    Anterior Segment Anatomic Parameters Based on the Scleral Spur and Cornea for Risk Profiling of Primary Angle-closure Glaucoma
    Actual Study Start Date :
    Nov 22, 2022
    Actual Primary Completion Date :
    Dec 31, 2022
    Actual Study Completion Date :
    Feb 28, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    primary angle-closure glaucoma
    narrow angle

    Outcome Measures

    Primary Outcome Measures

    1. Trabecular scleral-spur angle [2022-11-22 to 2022-12.31]

      The angle between the line of the corneal endothelium 750 μm from the scleral spur to the scleral spur and the bilateral line of the scleral spur

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    30 Years to 92 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Primary angle-closure glaucoma （PACG) was defined as an occlusion angle with peripheral anterior synechiae and intraocular pressure (IOP) > 21 mmHg or associated with glaucomatous optic neuropathy. The following conditions were identified as possible glaucomatous optic neuropathies, including a vertical cup-to-disc ratio ≥ 0.6, vertical cup-to-disc ratio asymmetry ≥ 0.2, optic disc haemorrhage, and visible retinal nerve fibre layer defect.

    2. Participants with narrow angle (NA) were selected from among patients with cataracts. NA was defined as a trabecular-iris angle (TIA) < 15° on anterior segment optical coherence tomography, with the exclusion of glaucomatous optic neuropathy or visual field loss.

    Exclusion Criteria:

    (1) severe systemic disease, (2) secondary angle-closure glaucoma, (3) other ocular diseases, (4) history of intraocular surgery, and (5) unclear examination images.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Zhongnan Hospital of Wuhan University Wuhan Hubei China 430071

    Sponsors and Collaborators

    • Min Ke

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Min Ke, Professor of Treatment, Zhongnan Hospital
    ClinicalTrials.gov Identifier:
    NCT06143943
    Other Study ID Numbers:
    • 20231116
    First Posted:
    Nov 22, 2023
    Last Update Posted:
    Nov 22, 2023
    Last Verified:
    Nov 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Glaucoma
    Glaucoma, Angle-Closure

    Study Results

    No Results Posted as of Nov 22, 2023